Alzheimer’s drug Lecanemab hailed as momentous breakthrough.
Trending news, read the latest BBC article here: The first drug to slow the destruction of the brain in Alzheimer’s has been heralded as momentous.
Earlier today, Dr Fraser Inglis, Founder and Director Research at Glasgow Memory Clinic, a NEUROCLIN centre commented…
“Very positive results announced last night from the CTAD 2022 Congress in San Francisco, regarding the EISAI, CLARITY study of Lecanemab.”
“Our most sincere congratulations to Eisai, BioArctic, Worldwide Clinical Trials and all Investigators, subjects and carers who have contributed to this ground breaking and landmark study.
An outstanding achievement with these positive results offering new hope to mankind”.
These results come 15 years after Glasgow Memory Clinic entered the first subject in Scotland in and Alzheimer’s Vaccine study – and 9 years after the clinic began work on Lecanemab when it was still in early development.
Work on Lecanemab continues with the AHEAD study – an Early Detection study that is currently running at the clinic.
Dr Inglis said “The AHEAD study takes the research focus to an even earlier stage of the Alzheimer’s illness – when subjects are unaware that toxic Amyloid protein is silently accumulating in the brain – with no or minimal memory complaints.
The great hope now is because the CLARITY study shows positive results, that giving treatment with Lecanemab at an earlier stage of the disease process will yield even better results.
I am exceptionally proud of all the achievements and wonderful research team here at the centre.
This breakthrough will be a catalyst for an even greater focus on developing and refining much needed new and better treatments for Alzheimer’s disease”.
Play your part.
Volunteers who take part in clinical trials are vital to the process of improving medical care, and we are grateful to those who are able to put themselves forward to play a part in this. Read more about why every participant is essential to our success.
Register to take part and view our current studies here.
Posted 30th November 2022